Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS - Donanemab and another new drug for ...

The European Medicines Agency has revealed a list of five cities that are preferred as its new location by staff after Brexit, following warnings of a public health disaster if EU leaders pick the ...

Alvotech develops and manufactures AVT03. STADA Arzneimittel AG and Dr. Reddy’s Laboratories SA, have entered into agreements with Alvotech for the commercialization of AVT03, each partner with ...

DBV Technologies is a clinical-stage biopharmaceutical company focused on developing innovative treatments for food allergies and other serious medical conditions. Their flagship product, the Viaskin ...

Novartis' Kisqali receives a positive recommendation from EMA's CHMP for adjuvant treatment of early breast cancer, showing a ...

Sir, – The European Medicines Agency has recently approved the use of Elahere (mirvetuximab soravtansine). This is a very welcome development in the treatment of women with advanced ovarian cancers.

The UK’s chief Brexit negotiator, minister David Davis will fight to keep the European Medicines Agency in London, despite the country leaving the EU. The Financial Times has reported that the ...

The European Medicines Agency has said no to approving a new drug for Alzheimer's disease in the EU. Aducanumab does not appear to be effective at treating adults with early-stage symptoms ...

Alnylam Pharmaceuticals (ALNY) announced the submission of a Type II Variation to the European Medicines Agency for vutrisiran, an ...

announced today that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT03, a proposed biosimilar candidate to Prolia® and Xgeva® (denosumab).